Walleye Capital
VRTX icon

Walleye Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Walleye Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.42M Sell
9,900
-4,700
-32% -$2.19M 0.02% 878
2025
Q4 		$6.62M Buy
14,600
+14,000
+2,333% +$6.03M 0.02% 936
2025
Q3 		$235K Sell
600
-8,700
-94% -$3.64M ﹤0.01% 3209
2025
Q2 		$4.14M Sell
9,300
-1,100
-11% -$507K 0.02% 994
2025
Q1 		$5.04M Buy
10,400
+4,400
+73% +$2.05M 0.02% 779
2024
Q4 		$2.42M Sell
6,000
-6,800
-53% -$3.15M 0.01% 1610
2024
Q3 		$5.95M Sell
12,800
-5,900
-32% -$2.83M 0.01% 1047
2024
Q2 		$8.77M Sell
18,700
-22,800
-55% -$9.9M 0.02% 857
2024
Q1 		$17.3M Buy
41,500
+31,900
+332% +$13.5M 0.03% 501
2023
Q4 		$3.91M Sell
9,600
-44,800
-82% -$16.5M 0.01% 1261
2023
Q3 		$18.9M Buy
54,400
+50,400
+1,260% +$17.6M 0.05% 282
2023
Q2 		$1.41M Sell
4,000
-2,400
-38% -$809K 0.01% 1571
2023
Q1 		$2.02M Buy
6,400
+600
+10% +$180K 0.03% 718
2022
Q4 		$1.67M Buy
5,800
+200
+4% +$61K 0.03% 679
2022
Q3 		$1.62M Buy
+5,600
New +$1.61M 0.03% 670
2020
Q2 		– Sell
-1,900
Closed -$452K – 985
2020
Q1 		$452K Sell
1,900
-11,500
-86% -$2.64M 0.1% 250
2019
Q4 		$2.93M Buy
13,400
+3,700
+38% +$749K 0.19% 122
2019
Q3 		$1.64M Buy
9,700
+2,700
+39% +$478K 0.1% 271
2019
Q2 		$1.28M Buy
7,000
+6,200
+775% +$1.08M 0.14% 196
2019
Q1 		$147K Buy
+800
New +$148K 0.02% 894

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Walleye Capital's VRTX Position: Q1 2026 in Review

Walleye Capital increased its Vertex Pharmaceuticals (VRTX) stake by 105% in Q1 2026, buying an estimated $7.36M and bringing the position to 30,752 shares worth $13.7M. The position accounts for 0.06% of the portfolio, ranked #291.

Walleye Capital first reported a position in VRTX in Q1 2019 and has held it in 26 quarters since. The position peaked at $19.4M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Walleye Capital held 30,752 shares of Vertex Pharmaceuticals worth $13.7M as of Q1 2026.
  • Walleye Capital bought 15,778 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.36M.
  • Vertex Pharmaceuticals made up 0.06% of Walleye Capital's portfolio in Q1 2026, its #291 holding.
  • Walleye Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Walleye Capital's Vertex Pharmaceuticals position peaked at $19.4M in Q3 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.